Leicester Tigers are the most successful rugby union side in England who have won their league a record 10 times since 1987. Leicester are also the only English side to have qualified to play in every Heineken Cup in which English teams have participated, and are also the most successful English side in Europe
The Tigers are supported by a world class sports medicine department who constantly strive to maintain the players in peak physical condition and when injuries inevitably occur, aim to make them stronger, better and less injury prone than before.
FLEXISEQ are proud to supply the Leicester Tigers medical staff, to help look after the joints of the athletes under their care.
Friday, 23 May 2014: A new drug-free treatment for arthritis is becoming a hit with top sports stars. The topically applied gel, Flexiseq, was developed to ease osteoarthritis pain but elite athletes including South African rugby players are using it to lubricate joints in readiness for wear and tear on the pitch.
Saracens Rugby Club has been trialling the revolutionary gel for the past six months. Tomorrow, the 2014 Heineken Cup Final takes place in Cardiff with Saracens versus reigning champions RC Toulon. Many South Africans play for Saracens including Mouritz Botha, Schalk Brits, Neil de Kock, Petrus du Plessis, Nick Fenton-Wells, Alastair Hargreaves, Justin Melck and Ernst Joubert as well as SA born and raised Brad Barritt. The technical director is Dr Brendan Venter. Jacques Burger from Namibia is also included.
What is not known is that many of these players are using a breakthrough joint care innovation, which has just become available in the last month in South Africa. The Saracens medical staff have been trialling Flexiseq amongst the players of the elite squad for the last six months.
Friday, 2 May 2014: South Africa’s osteoarthritis sufferers are desperate to ease their pain. So desperate in fact, that a medical breakthrough treatment, a gel, has sold out within three weeks of arriving in the country.
Ken Ralston, MD of SkyMed who has brought joint pain treatment Flexiseq into the country explains, “We calculated what stock we would need for three months and imported this. We have been astounded at the demand. We sold our last tube last week after three weeks of sales.”
Lawrence Gerber, Dis-Chem Fourways store manager comments, “Initially we asked for six units of Flexiseq. People started coming in asking for it as they had read about it in the paper. We then ordered 72 units and that also wasn’t enough. We have substantially increased our order. It was very extremely strong demand for a brand new product which wasn’t being advertised.”
Monday, 7 April 2014: There is new hope for more than three million osteoarthritis and joint pain sufferers in South Africa. Osteoarthritis is the world’s most prevalent joint disease. This new hope is due to a scientific breakthrough which, by means of innovative nano technology, enables damaged joints to be adequately lubricated giving pain relief and restoring joint mobility.
The effects of pioneering joint pain treatment Flexiseq gel were measured in six multicentre controlled clinical trials involving over 4,000 patients published in international peer review journals. In all trials, patients experienced reduced pain and improved joint mobility. In one large trial, Flexiseq was shown to be as effective as celecoxib, a billion dollar best-selling osteoarthritis drug.
Flexiseq was awarded the Innovation Award 2013 by the Federal Association of German Pharmacists for Flexiseq’s breakthrough approach to treatment of osteoarthritis enabled by the science of Sequessome Technology.
What is osteoarthritis?
There are over 200 different types of arthritis. The most common is osteoarthritis.
It is by far the most prevalent joint disease worldwide. In South Africa it is estimated that over 3.2 million people suffer from osteoarthritis (OA/RA Facts Finding 2006).
Osteoarthritis is a degenerative joint disease characterised by a lack of cartilage in the affected joint.
The layer of cartilage provides a shock absorbing and lubricating surface for the joint to move. So if cartilage is depleted or if lubrication is reduced (reduced phospholipids on cartilage), movement becomes more difficult and increased friction between the bones results in pain, inflammation and discomfort.
The condition is not reversible and often progressive, leading to increased pain and disability. Whilst it can occur in any joint, it is more likely to occur in joints that have been continually stressed over the years eg. knees, hips, feet, hands and lower spine.
Berlin, Germany, 25 October 2013
The International success of the breakthrough German therapy for osteoarthritis, FLEXISEQ™, was reported at a Healthcare Congress in Berlin today. FLEXISEQ is a safe*, effective and drug-free alternative in the treatment of osteoarthritis pain and joint stiffness. FLEXISEQ was reported as being nicknamed a "Wondergel" by patients and the press across the test markets in Europe. The gel contains no pharmacologically active substances, but works through the use of Sequessome™ vesicles, tiny phospholipid spheres that penetrate the skin, into the joint and lubricate the damaged cartilage. FLEXISEQ has already received the Innovation Award 2013 from the Federal Association of German Pharmacists for its innovative Sequessome Technology®.
28th January 2014, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK national launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis1 (OA) following the successful conclusion of the pioneering 2 month Charity partnership phase for the benefit of Arthritis Research UK. The contribution in products that are sold through the Arthritis Research UK website and through LloydsPharmacy has raised over £400,000 for the medical research charity. Sufferers have enthusiastically welcomed the new, effective and safe product that they can self-medicate and it is now going on sale through all leading pharmacies in the
UK. FLEXISEQ comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions and so is safer than the existing drug treatments.
3rd December 2013, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK Charity launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis₁ (OA). FLEXISEQ's proven efficacy comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions, and with over 6 million doses administered since launch there have been no reported systemic side effects.
FLEXISEQ is already successfully sold in the early pilot markets of Austria, Germany, Ireland, Malaysia and Singapore. Earlier this year, FLEXISEQ won the Innovation Award 2013 from the Federal Association of German Pharmacists. In June, FLEXISEQ launched in Ireland and became the fastest growing over-the-counter product that pharmacies there had seen in recent times.
October 2013 – FLEXISEQ™, the award winning new drug-free treatment for Osteoarthritis is now available in Singapore. Clinically proven* in Europe to be as effective at pain relief as the prescription drug celecoxib, but with an excellent safety profile, Flexiseq has been hailed in Europe as a Wondergel*. Flexiseq has already won The Innovation Award 2013 from the Federal Association of German Pharmacists for its break through Nano Technology.
Berlin 25.1013 "Get people moving – experience success". This slogan of the German Congress of Orthopaedics and Trauma Surgery also held true for the symposium organised by Pro Bono Bio, which reported on a new, innovative and award-winning therapy option for osteoarthritis patients. Studies were presented proving the efficacy of the topical gel for pain and joint stiffness associated with osteoarthritis as well as personal experiences of the presenters with FLEXISEQ™ based on patient cases. FLEXISEQ contains no pharmacologically active substances, but works through the use of Sequessome™ vesicles, tiny phospholipid droplets that penetrate the skin into the joint and lubricate the damaged cartilage. Worldwide marketing of the gel, developed and produced in Germany, is pending after initial successes in Europe and Asia, as company head John Mayo reported.